Kirpizidis H G, Papazachariou G S
Department of Cardiology, 2 General IKA Hospital, Thessaloniki, Greece.
Cardiovasc Drugs Ther. 1995 Feb;9(1):141-3. doi: 10.1007/BF00877754.
The effects of fosinopril and nifedipine on left ventricular (LV) mass were evaluated in 35 hypertensive patients with LV mass index greater than 110 g/m2 in female and 130 g/m2 in male patients. The goal of therapy was also to obtain a seated diastolic blood pressure (SDBP) of less than 90 mmHg. The patients were studied by echocardiography after 2 weeks of placebo treatment and 4, 12, and 24 weeks of monotherapy with active drugs. Both fosinopril and nifedipine reduced SDBP to a normal level after 6 months of treatment (p < .001). Regression of LV hypertrophy was achieved by either agent (p < .001), with fosinopril being more effective than nifedipine (p < .002). In conclusion, both fosinopril and nifedipine effectively reduce SDBP and achieve important regression of LV hypertrophy.
在35名左心室质量指数女性大于110 g/m²、男性大于130 g/m²的高血压患者中，评估了福辛普利和硝苯地平对左心室（LV）质量的影响。治疗目标还包括使坐位舒张压（SDBP）低于90 mmHg。在安慰剂治疗2周以及使用活性药物单药治疗4周、12周和24周后，通过超声心动图对患者进行研究。治疗6个月后，福辛普利和硝苯地平均将SDBP降至正常水平（p < .001）。两种药物均可使左心室肥厚消退（p < .001），福辛普利比硝苯地平更有效（p < .002）。总之，福辛普利和硝苯地平均可有效降低SDBP并使左心室肥厚显著消退。
